# Quanome Technologies, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Quanome Technologies, Inc.).

## Overview

Quanome Technologies, Inc. is a U.S.-based integrated cross-border supply chain provider focused on freight moving between Asia and the United States, particularly China and South Korea. Its services combine ocean and air freight forwarding, consolidation, customs clearance, warehousing, distribution, and U.S. domestic ground transportation, alongside a China-based pharmaceutical distribution business operated through Hupan Pharmaceutical.

## Products & services

• Cross-border ocean freight consolidation and forwarding
• Cross-border airfreight solutions
• Customs clearance and declaration services
• Warehousing, repackaging, and distribution
• U.S. domestic ground transportation
• Pharmaceutical and medical product distribution

- **Cross-Border Ocean Freight** (45%) — Consolidation and forwarding of Asian consumer and industrial goods into the United States.
- **Cross-Border Airfreight** (25%) — Air cargo forwarding and related handling services for time-sensitive shipments.
- **Customs, Warehousing and Distribution** (15%) — Customs clearance, warehouse handling, repackaging, and distribution supporting freight movements.
- **U.S. Domestic Ground Transportation** (5%) — Ground delivery services connecting imported freight with U.S. business and residential destinations.
- **Pharmaceutical Distribution** (10%) — Procurement, storage, and distribution of infusion fluids, specialty drugs, and medical nutrition products in China.

- Cross-border ocean freight consolidation and forwarding
- Cross-border airfreight solutions
- Customs clearance and declaration services
- Warehousing, repackaging, and distribution
- U.S. domestic ground transportation
- Pharmaceutical and medical product distribution

## Customers

The logistics business primarily serves Asia- and U.S.-based logistics companies that support large e-commerce platforms, social commerce platforms, and manufacturers selling Asian-made goods in the United States. These customers purchase integrated freight, customs, warehousing, and delivery services to simplify cross-border transportation and reduce supply-chain coordination requirements. The pharmaceutical business serves Chinese distributors, hospitals, clinics, and other healthcare providers, with products sourced from manufacturers and delivered through warehouses or agents. The company reported more than 400 customers and over 55,500 cross-border supply-chain orders as of June 30, 2025.

- **Asia- and U.S.-based Logistics Companies** (primary) — Buy outsourced freight forwarding, customs, warehousing, and delivery capacity for their end customers.
- **E-commerce and Social Commerce Platforms** (primary) — Use integrated cross-border logistics to move high volumes of Asian consumer goods into U.S. markets.
- **Manufacturers and Importers** (primary) — Purchase transportation and supply-chain coordination for consumer and industrial products made in Asia.
- **Chinese Pharmaceutical Distributors** (secondary) — Purchase infusion fluids, prescription products, and medical nutrition products for downstream distribution.
- **Hospitals, Clinics, and Healthcare Providers** (secondary) — Buy pharmaceutical and medical products for patient care and institutional use in China.

- Asian logistics companies serving U.S.-bound cargo
- U.S. logistics companies coordinating Asian imports
- E-commerce and social commerce supply chains
- Manufacturers moving consumer and industrial goods
- Chinese hospitals, clinics, and pharmaceutical distributors

## Geography

Quanome was founded in Chicago, Illinois, and its logistics network connects Asian origin markets with customers and delivery destinations across the United States. China and South Korea are identified as strategic Asian markets, while the company has used global freight carriers, domestic ground carriers, and regional warehousing facilities to serve U.S. shipments. Its logistics operations have delivered freight to thousands of business and residential addresses in approximately 48 U.S. states. Hupan Pharmaceutical is headquartered in Wuhan, China, and its pharmaceutical customers and distribution activity are concentrated in the Chinese market.

- Chicago-based U.S. platform for cross-border logistics
- China and South Korea are core Asian trade markets
- Freight delivered across approximately 48 U.S. states
- Wuhan, China is the base for pharmaceutical distribution
- China operations create Renminbi-to-USD exposure

## Strategy

The company is using its cross-border carrier, warehousing, and customs network to deepen integrated logistics services for Asia-to-U.S. trade flows. Its continuing operations are increasingly centered on Hupan Pharmaceutical, which distributes infusion products, specialty prescription drugs, and medical nutrition products through Chinese healthcare channels. Strategic priorities include expanding the customer base, improving service variety and technology-enabled execution, and managing the regulatory and working-capital requirements of pharmaceutical distribution. The company has also evaluated digital-asset opportunities through newly formed entities, although no such business had commenced and no concrete operating plan had been adopted in the cited report.

- **Expand the customer base** (short-term) — Customer growth supports order volumes and utilization of the integrated service network.
- **Increase logistics service breadth** (medium-term) — Combining forwarding, customs, warehousing, and delivery can improve customer retention and service value.
- **Scale pharmaceutical distribution in China** (medium-term) — The segment adds a healthcare distribution channel but requires regulatory and inventory controls.
- **Strengthen technology and operating controls** (medium-term) — Data security, shipment coordination, and service reliability are important competitive factors in fragmented freight markets.

- Expand the logistics and pharmaceutical customer base
- Broaden integrated freight and value-added services
- Use technology to improve shipment visibility and reliability
- Develop Chinese pharmaceutical distribution channels
- Maintain qualified carrier and supplier relationships
- Evaluate new opportunities without a launched digital-asset business

## Risks

Quanome operates in fragmented and highly competitive freight markets where larger providers may have greater financial resources, brand recognition, and carrier access. Its cross-border model is exposed to transportation capacity, customs rules, trade restrictions, tariffs, geopolitical conditions, and changes in carrier or supplier performance. The pharmaceutical expansion adds Chinese healthcare regulatory, product-quality, inventory, and working-capital risks, while China-centered operations create foreign-exchange exposure and customer-collection risk. The business also carries lease, loan, and convertible-note obligations that can constrain financial flexibility.

- **Transportation carrier dependency** [high] — The company relies on global freight carriers and domestic ground carriers for delivery capacity and execution.
- **Customs and trade-policy changes** [high] — Cross-border shipments can be affected by customs modernization, quotas, trade accords, tariffs, and governmental restrictions.
- **Pharmaceutical regulatory compliance** [high] — Medical-product handling and distribution require compliance with heightened healthcare, safety, storage, and quality requirements.
- **Pharmaceutical inventory and working capital** [high] — The company purchases products, holds them in designated warehouses, and may face cash strain before customer collection.
- **Foreign exchange and receivables collection** [medium] — China operations are reported in U.S. dollars while customers may pay in Renminbi and main customer terms extend 60-90 days.
- **Competitive pressure** [high] — Freight forwarding is fragmented, and competitors may have greater scale, technology investment, or customer recognition.

- Large logistics competitors may have stronger resources and brands
- Carrier capacity and service quality can change unexpectedly
- Customs, trade restrictions, and tariffs can disrupt shipments
- Pharmaceutical distribution raises regulatory and product-quality risk
- Inventory holdings increase working-capital requirements
- China operations create currency and collection exposure

## Accounting

Quanome prepares its consolidated financial statements under U.S. GAAP, with common stock warrants requiring classification analysis under ASC 480 and ASC 815; liability classification can create valuation changes in reported results. Pharmaceutical distribution requires analysis of product revenue, inventory, rebates and discounts, and the timing of delivery to distributors, hospitals, and clinics. Analysts should also monitor foreign-currency translation from China operations, collectability of 60-90 day receivables, lease obligations, and acquisition-related intangible assets. The business's shift between freight services and pharmaceutical distribution can affect comparability of revenue, cost of revenue, working capital, and segment performance.

- **Common stock warrants** — Liability classification can create fair-value changes through reported earnings.
- **Pharmaceutical revenue recognition** — Delivery terms, rebates, discounts, and principal-versus-agent judgments affect revenue timing and amount.
- **Inventory and cost of revenue** — Inventory valuation, product costs, and potential obsolescence affect gross profit and working capital.
- **Foreign-currency translation** — Renminbi movements can change reported revenue, assets, liabilities, and profitability.
- **Receivables and collectability** — Credit losses or delayed collection can reduce operating cash flow and require allowances.
- **Leases and acquired intangibles** — Lease measurement, depreciation, amortization, and impairment estimates affect assets and operating expenses.

- Warrant classification can create liability remeasurement volatility
- Pharmaceutical revenue timing depends on delivery and customer terms
- Inventory accounting includes product costs, rebates, and discounts
- Renminbi translation affects reported U.S. dollar results
- Receivable collectability affects cash flow and provisions
- Lease and acquired-intangible estimates affect expenses and assets

---

*Last updated: 2026-09-24T12:19:27.716193+00:00*